| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1858 | 2009 |
| Large-scale association analysis identifies new risk loci for coronary artery disease CARDIoGRAMplusC4D Consortium, P Deloukas, S Kanoni, C Willenborg, ... Nature genetics 45 (1), 25-33, 2013 | 1764 | 2013 |
| A randomized trial of genotype-guided dosing of warfarin M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ... New England Journal of Medicine 369 (24), 2294-2303, 2013 | 968 | 2013 |
| A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose F Takeuchi, R McGinnis, S Bourgeois, C Barnes, N Eriksson, N Soranzo, ... PLoS genetics 5 (3), e1000433, 2009 | 771 | 2009 |
| The largest prospective warfarin-treated cohort supports genetic forecasting M Wadelius, LY Chen, JD Lindh, N Eriksson, MJR Ghori, S Bumpstead, ... Blood, The Journal of the American Society of Hematology 113 (4), 784-792, 2009 | 710 | 2009 |
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose M Wadelius, LY Chen, K Downes, J Ghori, S Hunt, N Eriksson, ... The pharmacogenomics journal 5 (4), 262-270, 2005 | 643 | 2005 |
| Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of … N Wahlgren, N Ahmed, N Eriksson, F Aichner, E Bluhmki, A Dávalos, ... Stroke 39 (12), 3316-3322, 2008 | 598 | 2008 |
| Association of warfarin dose with genes involved in its action and metabolism M Wadelius, LY Chen, N Eriksson, S Bumpstead, J Ghori, C Wadelius, ... Human genetics 121, 23-34, 2007 | 534 | 2007 |
| The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals GB Ehret, T Ferreira, DI Chasman, AU Jackson, EM Schmidt, T Johnson, ... Nature genetics 48 (10), 1171-1184, 2016 | 449 | 2016 |
| Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals L Folkersen, S Gustafsson, Q Wang, DH Hansen, ÅK Hedman, A Schork, ... Nature metabolism 2 (10), 1135-1148, 2020 | 433 | 2020 |
| Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ... Blood, The Journal of the American Society of Hematology 115 (18), 3827-3834, 2010 | 407 | 2010 |
| Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA M Wieloch, A Själander, V Frykman, M Rosenqvist, N Eriksson, ... European heart journal 32 (18), 2282-2289, 2011 | 354 | 2011 |
| Genetic determinants of dabigatran plasma levels and their relation to bleeding G Paré, N Eriksson, T Lehr, S Connolly, J Eikelboom, MD Ezekowitz, ... Circulation 127 (13), 1404-1412, 2013 | 335 | 2013 |
| Integration of genetic, clinical, and INR data to refine warfarin dosing P Lenzini, M Wadelius, S Kimmel, JL Anderson, AL Jorgensen, ... Clinical Pharmacology & Therapeutics 87 (5), 572-578, 2010 | 267 | 2010 |
| Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International … N Ahmed, A Davalos, N Eriksson, GA Ford, J Glahn, M Hennerici, ... Archives of neurology 67 (9), 1123-1130, 2010 | 216 | 2010 |
| STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk AK Abelson, AM Delgado-Vega, SV Kozyrev, E Sanchez, ... Annals of the rheumatic diseases 68 (11), 1746-1753, 2009 | 170 | 2009 |
| Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets JH Zhao, D Stacey, N Eriksson, E Macdonald-Dunlop, ÅK Hedman, ... Nature immunology 24 (9), 1540-1551, 2023 | 168 | 2023 |
| Effect of genetic variations on ticagrelor plasma levels and clinical outcomes C Varenhorst, N Eriksson, A Johansson, BJ Barratt, E Hagström, ... European heart journal 36 (29), 1901-1912, 2015 | 148 | 2015 |
| Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation L Wallentin, J Lindbäck, N Eriksson, Z Hijazi, JW Eikelboom, ... European heart journal 41 (41), 4037-4046, 2020 | 119 | 2020 |
| Prediction of warfarin dose: why, when and how? N Eriksson, M Wadelius Pharmacogenomics 13 (4), 429-440, 2012 | 117 | 2012 |
